Paper Details

  1. Home
  2. Paper Details

Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report.

Author: KayhanBurcak, OzkanAysegul Ertinmaz, SevencanNurhayat Ozkan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study reviews the evidence regarding linagliptin, a dipeptidyl peptidase-4 inhibitor, and its potential to cause pancreatitis. While other dipeptidyl peptidase-4 inhibitors have been linked to pancreatitis, there is no clear evidence suggesting that linagliptin causes pancreatitis.
Paper Details　
Original Abstract of the Article :
Dipeptidyl peptidase-4 inhibitors are commonly used drugs for the treatment of type 2 diabetes mellitus. While acute pancreatitis cases induced by saxagliptin, sitagliptin, and vildagliptin (all of which are members of the dipeptidyl peptidase-4 group) have been reported, there is no clear evidence ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320078/

データ提供：米国国立医学図書館（NLM）

A Rare Oasis: Linagliptin and Pancreatitis

Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used medications for managing type 2 diabetes. This case report describes a patient with biliary calculus who experienced pancreatitis while taking linagliptin, a DPP-4 inhibitor. While previous reports have linked other DPP-4 inhibitors, such as saxagliptin, sitagliptin, and vildagliptin, to pancreatitis, this case provides limited evidence suggesting a potential association between linagliptin and pancreatitis.

A Desert of Uncertainty: Understanding Drug-Induced Pancreatitis

This case report adds a piece to the puzzle of drug-induced pancreatitis. While the association between linagliptin and pancreatitis remains unclear, it highlights the importance of continued vigilance and further research to understand the potential risks associated with DPP-4 inhibitors.

A Desert of Uncertainty: Navigating Diabetes Treatment

Imagine a diabetic patient navigating the desert of managing their condition. This case report serves as a reminder of the potential for unexpected side effects, even with widely used medications. It underscores the importance of close monitoring and communication with healthcare providers to identify and address any potential complications.

Dr.Camel's Conclusion

This case report raises questions about the potential association between linagliptin and pancreatitis. While further research is needed to determine the extent of this association, it underscores the importance of continued vigilance and open communication between patients and healthcare providers regarding potential side effects of medications.

Date :
  1. Date Completed 2019-01-07
  2. Date Revised 2022-10-05
Further Info :

Pubmed ID

30557974

DOI: Digital Object Identifier

PMC6320078

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.